Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer

Yamaç, Deniz; Öztürk, Bayram; Coşkun, Uğur; Tekin, Ercüment; Sancak, Banu; Yıldız, Ramazan; Atalay, Can

doi:10.1007/s12325-008-0082-2

Cited by 33 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several different cancer types circulating levels of YKL-40 are increased and correlated to poor prognosis and short survival time, such as colorectal cancer (Cintin et al 1999(Cintin et al , 2002, small cell lung cancer (Johansen et al 2004), gastric cancer (Bi et al 2009), melanoma (Schmidt et al 2006), chondroid tumours (Daugaard et al 2009), Hodgkin lymphoma (Biggar et al 2008), cervical adenocarcinoma (Mitsuhashi et al 2009), multiple myeloma (Mylin et al 2006), acute myeloid leukaemia (Bergmann et al 2005), breast cancer (Jensen et al 2003;Yamac et al 2008), ovarian cancer (Dupont et al 2004;Hogdal et al 2009;Yang et al 2009) and prostate cancer (Kucur et al 2008). This indicates, that it is not related to the pathogenesis of a single cancer type, but more a general response to the development and spread of cancer cells.…”

Section: Malignant Diseasesmentioning

confidence: 99%

Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

Kastrup

2012

Immunobiology

View full text Add to dashboard Cite

Section: Malignant Diseasesmentioning

confidence: 99%

Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

Kastrup

2012

Immunobiology

View full text Add to dashboard Cite

“…In addition, patients with metastatic breast cancer had significantly higher serum concentration of YKL40 when compared with the control group (Jensen et al . 2003, Yamac et al . 2008).…”

Section: Introductionmentioning

confidence: 99%

Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells

Jeet

Tevz

Lehman

et al. 2014

Endocrine Related Cancer

View full text Add to dashboard Cite

Chitinase 3-like 1 (CHI3L1 or YKL40) is a secreted glycoprotein highly expressed in tumours from patients with advanced stage cancers, including prostate cancer (PCa). The exact function of YKL40 is poorly understood, but it has been shown to play an important role in promoting tumour angiogenesis and metastasis. The therapeutic value and biological function of YKL40 are unknown in PCa. The objective of this study was to examine the expression and function of YKL40 in PCa. Gene expression analysis demonstrated that YKL40 was highly expressed in metastatic PCa cells when compared with less invasive and normal prostate epithelial cell lines. In addition, the expression was primarily limited to androgen receptor-positive cell lines. Evaluation of YKL40 tissue expression in PCa patients showed a progressive increase in patients with aggressive disease when compared with those with less aggressive cancers and normal controls. Treatment of LNCaP and C4-2B cells with androgens increased YKL40 expression, whereas treatment with an anti-androgen agent decreased the gene expression of YKL40 in androgen-sensitive LNCaP cells. Furthermore, knockdown of YKL40 significantly decreased invasion and migration of PCa cells, whereas overexpression rendered them more invasive and migratory, which was commensurate with an enhancement in the anchorage-independent growth of cells. To our knowledge, this study characterises the role of YKL40 for the first time in PCa. Together, these results suggest that YKL40 plays an important role in PCa progression and thus inhibition of YKL40 may be a potential therapeutic strategy for the treatment of PCa.

show abstract

“…A study by Yamac et al, (2008) demonstrated that the median serum YKL-40 concentration in patients with locally advanced breast cancer was 149.5 ìg/ml and it was higher than levels observed in healthy female controls. It was suggested that YKL-40 may be a useful prognostic indicator of outcome for patients with locally advanced breast cancer (31).…”

Section: Discussionmentioning

confidence: 94%

“…It was suggested that YKL-40 may be a useful prognostic indicator of outcome for patients with locally advanced breast cancer (31).…”

Section: Discussionmentioning

confidence: 99%

Ykl-40 in Sera of Breast Tumor Patients

Kazakova¹

2010

JofIMAB

View full text Add to dashboard Cite

SUMMARY YKL-40, also known as human cartilage glycoprotein 39, is a member of the "mammalian chitinase-like proteins", but lacking of chitinase activity. Increased variations in serum concentrations are associated with inflammatory processes and several types of cancer.In this study we evaluated serum YKL-40 levels in healthy controls and in women with benign and malignant breast tumors.YKL-40 serum levels were measured by enzyme-linked immunosorbent assay -ELISA in 32 patients. The effect of the various factors was analyzed using correlation and regression analyses simultaneously determining the size and direction of correlation. The level of statistical significance of null hypothesis was P<0.05.Our study showed that serum YKL-40 level in breast carcinoma was significantly higher than the concentration in healthy controls (p<0.01). The changes in protein levels were higher than 25%. Serum YKL-40 increased with age (rxy=0.46). The correlation between glycoprotein quantity and age was positive, but feeble.This investigation is first in Bulgaria to demonstrate significantly elevated serum YKL-40 level in breast carcinoma compared to women with benign breast tumors and healthy controls. Longitudinal studies are needed to confirm YKL-40 as a potential and reliable biomarker.

show abstract

Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer

Abstract: Our results show that serum levels of the growth factor YKL-40 may be a useful prognostic indicator of outcome for patients with locally advanced breast cancer. Further studies are required to fully elucidate the biological function of YKL-40 in breast cancer.

Cited by 33 publications

References 22 publications

Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells

Ykl-40 in Sera of Breast Tumor Patients

Contact Info

Product

Resources

About